Our Science

Science

Genetic medicine needs a paradigm shift.

The promise of genetic medicine to cure diseases is falling short because:

We are working to address all of these challenges.

Technology

Using ultrasound-mediated delivery

SonoThera is developing a proprietary, nonviral, non-invasive, immune stealth approach which enables:

RIPPLE

content-image

SonoThera exclusively holds the foundational IP on RIPPLE™ technology enabling safe, efficient, immune stealth and uniform biodistribution.


RIPPLE™
(Remote Induction of Pulsed Pressure Lateral to Energy)

Pipeline

SonoThera is advancing its therapeutic programs in several areas: muscle, kidney, liver, heart, and CNS.

We have presented data publicly specific to the following diseases:

We are poised to initiate our first human clinical trial in 2027 with a pipeline of several INDs following, supporting a steady cadence of clinical data through 2028.

Inquiries about our Clinical Research